...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Epidemiology and Genetics >Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study
【24h】

Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study

机译：西班牙裔和非西班牙裔白人女性中的表皮生长因子受体（EGFR）多态性与乳腺癌：乳腺癌健康差异研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The epidermal growth factor receptor (emEGFR/em), a member of the ErbB family of receptor tyrosine kinases, functions in cellular processes essential to the development of cancer. Overexpression of emEGFR/em in primary breast tumors has been linked with poor prognosis. We investigated the associations between 34 emEGFR/em tagging SNPs and breast cancer risk and breast cancer-specific mortality in 4,703 Hispanic and 3,030 non-Hispanic white women from the Breast Cancer Health Disparities Study. We evaluated associations with risk of breast cancer defined by estrogen/progesterone receptor (ER/PR) tumor phenotype. Only one association remained statistically significant after adjusting for multiple comparisons. Rs2075112subGA/AA/sub was associated with reduced risk for ER-/PR+ tumor phenotype (odds ratio (OR), 0.34; 95% confidence interval (CI) 0.18-0.63, p adj=0.01). All additional results were significant prior to adjustment for multiple comparisons. Two of the emEGFR/em polymorphisms were associated with breast cancer risk in the overall study population (rs11770531subTT/sub: OR, 0.56, 95% CI 0.37-0.84; and rs2293348subAA/sub: OR, 1.20, 95% CI 1.04-1.38) and two polymorphisms were associated with risk among Hispanics: rs6954351subAA/sub: OR, 2.50, 95% CI 1.32-4.76; and rs845558subGA/AA/sub: OR, 1.15, 95% CI 1.01-1.30. With regard to breast cancer-specific mortality, we found positive associations with rs6978771subTT/sub hazard ratio (HR), 1.68; 95% CI 1.11-2.56; rs9642391subCC/sub HR, 1.64; 95% CI 1.04-2.58; rs4947979subAG/GG/sub HR, 1.36; 95% CI 1.03-1.79; and rs845552subGG/sub HR, 1.62; 95% CI 1.05-2.49. Our findings provide additional insight for the role of emEGFR/em in breast cancer development and prognosis. Further research is needed to elucidate emEGFR/em’s contribution to ethnic disparities in breast cancer.
机译：表皮生长因子受体（ EGFR ）是受体酪氨酸激酶ErbB家族的成员，在癌症发展所必需的细胞过程中起作用。原发性乳腺肿瘤中 EGFR 的过表达与预后不良有关。我们通过乳腺癌健康差异研究调查了4,703名西班牙裔和3,030名非西班牙裔白人女性中34种 EGFR 标记SNP与乳腺癌风险和乳腺癌特异性死亡率之间的关联。我们评估了雌激素/孕激素受体（ER / PR）肿瘤表型与乳腺癌风险的关联。调整多个比较后，只有一个关联在统计上仍然显着。 Rs2075112 GA / AA 与ER- / PR +肿瘤表型的风险降低相关（几率（OR）为0.34; 95％置信区间（CI）为0.18-0.63，p adj = 0.01）。在进行多次比较调整之前，所有其他结果都很重要。在整个研究人群中，有两个 EGFR 多态性与乳腺癌风险相关（rs11770531 TT ：或，0.56、95％CI 0.37-0.84;以及rs2293348 AA ：OR，1.20，95％CI 1.04-1.38）和两个多态性与西班牙裔患者的风险相关：rs6954351 AA ：OR，2.50，95％CI 1.32-4.76;和rs845558 GA / AA ：或，1.15，95％CI 1.01-1.30。关于乳腺癌的特异性死亡率，我们发现与rs6978771 TT 危险比（HR）为1.68正相关; 95％CI 1.11-2.56; rs9642391 CC HR，1.64; 95％CI 1.04-2.58; rs4947979 AG / GG HR，1.36; 95％CI 1.03-1.79;和rs845552 GG HR，1.62; 95％CI 1.05-2.49。我们的发现为 EGFR 在乳腺癌发展和预后中的作用提供了更多的见解。需要进一步的研究来阐明 EGFR ＆＃x02019;对乳腺癌种族差异的贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号